New CODP treatment gets FDA nod

Nov 12, 2018

Mylan and Theravance Biopharma have won approval for their inhalable treatment, Yupelri. 

Designed as a maintenance treatment for patients with chronic obstructive pulmonary disease, Yupelri is the first-ever once-daily, nebulized bronchodilator approved by the FDA for COPD. 

Around 16 million Americans have COPD, and the companies say that 9-10 percent of patients prefer a nebulized product to treat the condition. 

The companies plan to launch Yupelri in the U.S. later this year.  

Read the full Reuters report.

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments